Chevy Chase Trust Holdings LLC Has $183.22 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Chevy Chase Trust Holdings LLC decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 4.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 369,930 shares of the medical equipment provider's stock after selling 18,514 shares during the period. Intuitive Surgical makes up 0.6% of Chevy Chase Trust Holdings LLC's portfolio, making the stock its 27th largest position. Chevy Chase Trust Holdings LLC owned approximately 0.10% of Intuitive Surgical worth $183,215,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in ISRG. Vanguard Group Inc. lifted its stake in Intuitive Surgical by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock valued at $16,813,478,000 after buying an additional 360,591 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Intuitive Surgical by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider's stock worth $4,039,200,000 after acquiring an additional 243,802 shares during the period. Fisher Asset Management LLC lifted its position in Intuitive Surgical by 1.8% in the 4th quarter. Fisher Asset Management LLC now owns 4,868,869 shares of the medical equipment provider's stock valued at $2,541,356,000 after acquiring an additional 86,488 shares in the last quarter. Norges Bank bought a new stake in Intuitive Surgical in the 4th quarter valued at $2,401,493,000. Finally, Invesco Ltd. boosted its stake in Intuitive Surgical by 7.7% in the 4th quarter. Invesco Ltd. now owns 4,148,180 shares of the medical equipment provider's stock worth $2,165,184,000 after purchasing an additional 295,025 shares during the period. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Trading Down 0.3%

NASDAQ:ISRG traded down $1.45 on Wednesday, hitting $521.63. The company's stock had a trading volume of 1,177,810 shares, compared to its average volume of 1,673,768. Intuitive Surgical, Inc. has a one year low of $413.82 and a one year high of $616.00. The firm has a market capitalization of $186.96 billion, a P/E ratio of 76.49, a price-to-earnings-growth ratio of 5.46 and a beta of 1.67. The stock has a fifty day moving average of $529.22 and a two-hundred day moving average of $536.97.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. The business had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. During the same quarter in the prior year, the business earned $1.50 EPS. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Activity

In other news, Director Jami K. Nachtsheim sold 2,400 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the transaction, the director now owns 6,371 shares in the company, valued at approximately $3,312,920. This trade represents a 27.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $515.91, for a total value of $96,991.08. Following the sale, the executive vice president now directly owns 5,224 shares of the company's stock, valued at approximately $2,695,113.84. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,998 shares of company stock valued at $2,611,577 over the last ninety days. 0.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Robert W. Baird dropped their price target on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their target price for the company from $515.00 to $440.00 in a research report on Monday, June 9th. Evercore ISI reduced their price target on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a research report on Wednesday, April 23rd. Royal Bank Of Canada reduced their target price on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Finally, Barclays lowered their price target on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $588.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.